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Introduction
Endometrial cancer is one of the most frequently diag-
nosed cancer in females with prevalence of 22 in
100,000 women [1]. According to NIH report in USA
in 2008 developed  approximately 35000 new cases of
the disease and 7500 women died. Most cases occur in
women at the age over 60. The etiology of the cancer
remains unclear. Despite significant progress towards
understanding the patho-mechanism of the disease,
effective treatment is still lacking. 
Chemotherapy is indicated as frontline treatment
for endometrial cancer. Combination of Anthracy-
clines, platinum compounds, and taxanes produces
higher response rates, although combination regimens
have not always improved survival rate. Doxorubicin
plus cisplatin has been accepted as the Gynecologic
Oncology Group standard regimen based on phase 
III clinical data. Hormonal therapy is beneficial only in
specified group of patients [2].
From previous experiments it is known, that echis-
tatin an inhibitor of β1-integrin receptor contributes to
inhibition of collagen biosynthesis and decrease in the
expression of FAK, SOS-protein and phosphorylated
MAP-kinases, ERK1 and ERK2 [3]. Stimulated 
β1-integrin receptor induces autophosphorylation of
non-receptor protein kinase FAK [4], which is then
capable of interacting with adaptor-proteins, such as
Grb2, through Src and Shc proteins. This interaction
allows activating further cascade of signaling pathway
through Sos, Ras and Raf proteins [5] and subsequent-
ly, two MAP kinases: ERK1 and ERK2 [6]. The end
point of this cascade is induction of transcription fac-
tor(s) that regulate(s) gene expression of integrins,
proteinases and many proteins involved in regulation
of cell growth and differentiation [7]. 
Another potent stimulator of cell growth and colla-
gen biosynthesis is insulin like growth factor I [8]. IGF-
I interacting with its receptor stimulates proliferation,
enhances metastasis [9], prevents apoptosis [10]. IGF
receptor signaling pathway involves the same proteins
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as integrin receptor signaling cascade, except Src and
FAK proteins [11].
Melphalan represents one of nitrogen mustard
derivates, the group of earliest and effective antitumor
drugs used in cancer therapy [12]. It acts through for-
mation of  interstrand cross-links in major groove of
DNA [13]. Melphalan also inhibits collagen biosyn-
thesis in breast cancer cell lines [14] and was also pro-
posed as a component of combined therapy in metasta-
tic or recurrent endometrial carcinoma [15].
The present study was undertaken to evaluate the
effect of combined treatment of disintegrin, echistatin
and  melphalan on  collagen biosynthesis, expressions
of β1-integrin and IGF-I receptors and some signaling
proteins as Shc protein and FAK-kinases as well as on
cytotoxicity in endometrial cancer (Ishikawa) cells.
Materials and methods
Materials. Anti-Goat IgG antibody, Anti-Mouse IgG antibody, Fast
BCIP/NBT reagent, Nonidet P-40, were provided by Sigma Corp.,
USA., as were most other chemicals and buffers used. Dulbecco's
minimal essential medium (DMEM) and fetal bovine serum (FBS)
used in cell culture were products of Gibco, USA. Glutamine, peni-
cillin and streptomycin were obtained from Quality Biologicals Inc.,
USA. Nitrocellulose membrane (0,2 μm), sodium dodecylsulphate
(SDS), polyacrylamide, molecular weight standards were received
from Bio-Rad Laboratories, USA. L-5[3H] proline (28 Ci/mmol)
was purchased from Amersham, UK. Monoclonal (mouse) anti-
IGFR, anti Shc, anti-FAK antibodies were obtained from Becton
Dickinson Co., USA. Monoclonal (mouse) anti-β1-integrin anti-
body was obtained from ICN Biomedicals Inc., USA.
Tissue culture. All studies were performed on Ishikawa cell line
purchased in American Type Culture Collection, Rockville, MD.
The cells were maintained in DMEM supplemented with 5% fetal
bovine serum (FBS), 2 mmol/l glutamine, 50 U/ml penicillin, 
50  μg/ml streptomycin at 37°C in a 5% CO2 incubator. 
Cytotoxicity assay. Toxicity of evaluated compounds was deter-
mined by method of Plumb et al. [16]. Iskikawa cells were main-
tained as described above. After 48 h incubation of the cells with
drugs the medium was discarded and the cells were rinsed three
times with phosphate buffered saline (PBS). Then the cells were
incubated for 4 h in 2 ml of PBS with 50 μl of MTT (5mg/ml). Medi-
um was removed from the wells, and the cells were lyzed in 200 μl
of DMSO with 20 μl of Sorensen's buffer (0.1 M glycine with 0.1 M
NaCl, pH 10.5). The absorbance was measured at 570 nm.  
Collagen production. Incorporation of radioactive precursor into
proteins was measured after labeling of confluent cells in growth
medium with evaluated compounds  for 48 h with 5[3H]-proline (5
μCi/ml, 28 Ci/mM) as described by Peterkofsky et al. [17].
SDS-PAGE. Slab SDS/PAGE was used, according to the method
of Laemmli [18]. Samples of cell supernatants (25-50 μg of pro-
tein) were incubated for 10 min. at 100°C in 62.5 mmol/l Tris-HCl,
pH 6.8, containing 2.0% (w/v) SDS, 5% (v/v) β -mercaptoethanol,
10% (v/v) glycerol and 0.001% bromophenol blue. Samples were
electrophoresed on a Tris-Glycine gels at 100 V per gel for 30 min-
utes at room temperature. 
Western immunoblot analysis. After SDS-PAGE, the gels were
allowed to equilibrate for 5 min in 25 mmol/l Tris, 0.2 mol/l glicine
in 20% (v/v) methanol. The protein was transferred to 0.2 μm pore-
sized nitrocellulose at 100 mA for 90 minutes using a BioRad elec-
trophoresis unit according to the method described in the manual
accompanying the unit. The membrane was blocked with 5% dried
milk in TBS-T for 1 hour in room temperature, slowly shaking.
Then the nitrocellulose was incubated with monoclonal antibody
against β1-integrin, FAK, Shc or IGFR at concentration 1:5,000
overnight. After the incubation, nitrocellulose was washed with
TBS-T (1 x 15 min and 2 x 10 min) intensively shaking. In order
to analyze the proteins second alkaline phosphatase labeled anti-
bodies against mouse`s Fc IgG was added at concentration 1:2,500
in TBS-T and incubated for 1 hour slowly shaking. Then the mem-
brane was extensively washed with TBS-T (5 x 10 min) and sub-
mitted to BCIP/NBT western blotting detection system. 
Statistical analysis. In all experiments, the mean values for three
independent experiments ± standard deviation were calculated.
The results were submitted to statistical analysis using Student's t-
test, accepting p<0.05 as significant.
Results
To evaluate cytotoxic effect of echistatin and melphalan,
the viability of Ishikawa cells was measured by the
method of Plumb et al. [16]. Incubation of the cells for
24 h with disintegrin at concentrations 50 and 
100 ng/ml of medium had no significant effect on the
cell viability (Fig. 1).  Melphalan at concentrations 25,
50 and 75 μM induced decreased of the cell viability to
89, 82 and 76% of control value, respectively. Incubation
of Ishikawa cells with 50 ng/ml or 100 ng/ml of echis-
tatin for 24 h and then incubated for additional 
24 h with 25, 50 or 75 μM melphalan significantly
decreased the cell viability (Fig. 1). Different order of
added substrances produced much lower effects (not
shown).  
Similar effect was observed in respect to collagen
biosynthesis. The inhibition of the protein biosynthesis
was the most effective when the cells were treated with
disintegrin for 24 h and then with melphalan for 24 h
(Fig. 2).
Collagen biosynthesis is regulated by the signal
induced by β1-integrin receptor. Expression of the
receptor was evaluated by western immunoblot analy-
sis. Expression of the β1-integrin was not changed in
Ishikawa cell line treated with echistatin, melphalan or
both compounds (Fig. 3). 
Expression of proteins involved in signaling path-
way induced by stimulated β1-integrin receptor was
also evaluated. (Fig. 4) Treatment of the cells with
echistatin for 24 hours and then with melphalan,
induced decrease in the expression of Shc and phos-
phorylated FAK-proteins as compared to control cells
or the cells treated with both compounds alone  (Fig. 4).
Since IGF-I receptor plays important role in regula-
tion of mitogenesis, apoptosis and collagen biosynthe-
sis the expression of the receptor in Ishikawa cell line
treated with echistatin and melphalan was estimated.
As shown on Fig. 5. the expression of the receptor was
decreased in the cells treated with echistain for 24 h and
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than with melphalan for additional 24 h. Treatment of
the cells with respective compound alone had no effect
on the IGF receptor protein expression.
Discussion
The integrins familly are responsible for adhesion of
cells to extracellular matrix components as well as to
other cells [19]. The interaction  affects cytoskeleton
organization, lipid metabolism, kinase activation, gene
expression [20], cell cycle progression [21] and metas-
tasis [22]. β1 and β3 integrins play an important role in
tumor invasion [23]. 
Cell migration, invasion, matrix degradation, pro-
liferation, and angiogenesis are all mediated by inte-
grins and integrin signaling [24,25].
Ishikawa cells, similarly as  endometrial, epithelial
cells express integrins α2β1, α3β1, α6β4 [26]. α2β1 inte-
grin receptor is the main receptor for collagen and is
involved in regulation of collagen production [27].
Melphalan is one of the nitrogen mustard deriva-
tives, that represent the group of earliest and effective
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Fig. 1. Viability of Ishikawa cells treated with various concentra-
tions of echistatin (E) and malphalan (M). The cells were incubat-
ed for 48 h with echistatin at concentrations 50 and 100 ng/ml con-
dition medium or melphalan at concentrations 25, 50 and 75 μM.
Another set of the cells was treated with 50 ng/ml or 100 ng of
echistatin for 24 hours then melphalan was added to achieve con-
centrations 25, 50 and 75 μM, incubation continued for 24 hours.
Mean values from three independent experiments done in tripli-
cates +/- standard deviation are presented. *p<0.05.
Fig. 2. Collagen production, measured by 5-[3H]-proline incorpo-
ration into proteins susceptible to the action of bacterial collage-
nase in Ishikawa cell culture. The cells were incubated for 48 h
with echistatin  at concentrations 50 and 100 ng/ml condition
medium or melphalan at concentrations 25, 50 and 75 μM.
Another set of the cells was treated with 50 ng/ml or 100 ng of
echistatin for 24 hours then melphalan was added to achieve con-
centrations 25, 50 and 75 μM, incubation continued for 24 hours.
Mean values from three independent experiments done in tripli-
cates +/- standard deviation are presented. *p< 0.05.
Fig. 3. Western immunoblot analysis for β1-integrin receptor (A)
in Ishikawa cells treated with echistatin (E) and melphalan (M). β-
actin serves as a loading control (B). The result represent mean
from three independent experiments. Samples used to the experi-
ments consisted 50 μg of protein from pooled cell extracts.
Fig. 4. Western immunoblot analysis for Shc protein (A), FAK (B)
in Ishikawa cells treated with echistatin (E) and melphalan (M) as
described in Materials and methods section. The result represent
mean from three independent experiments. Samples used to the
experiments consisted 50 μg of protein from pooled cell extracts.  
Fig. 5. Western immunoblot analysis for IGF receptor in Ishikawa
cells treated with echistatin (E) and melphalan (M) as described in
Materials and methods section. The result represent mean from
three independent experiments. Samples used to the experiments
consisted 50 μg of protein from pooled cell extracts.
antitumor drugs used in cancer therapy [12,13], acting
through induction of interstrand cross-links in major
groove of DNA [12,13]. Melphalan is used in therapy
of  advanced cancer of the ovaries, multiple myeloma,
malignant melanoma, childhood neuroblastoma,  soft
tissue sarcoma. Side effects of melphalan include tox-
icity on  blood cells, platelets, lung and liver and may
contribute to nausea, diarrhea, mouth ulcers, hair loss,
skin rashes and  leukaemia. It is extremely important
to keep doses of anticancer drug as low as possible to
avoid serious side effects. 
Echistatin and other disintegrins have been exten-
sively studied in the past. It is now established that dis-
integrins are effective agents in limiting tumor growth
and spread [28,29].  Disintegrins interacting with sev-
eral integrins block various integrin-mediated process-
es involved in tumor growth, metastasis and angiogen-
esis [30]. 
The results of the study suggest that combined
treatment of Ishikawa cells with echistatin and mel-
phalan   severely inhibits important biological func-
tions of the cells. We showed that such strategy  have
a potent cytotoxic effect. The mechanism of the
process undergoes probably through inhibition of inte-
grin – dependent signaling. In this study we shown
down regulation of Shc and  FAK proteins in cells
treated with echistatin and melphalan. It suggests that
signaling pathways that involve Shc and FAK partici-
pation may represent target for antineoplastic strategy. 
The functional significance of the combined treat-
ment of Ishikwa cells with echistatin and melphalan
was found at the level of collagen biosynthesis.
Decreased biosynthesis of collagen in extracellular
matrix on one hand may faciliate motility and invasion
of neoplastc cells (31), but on another may suppress
cell growth and induce apoptosis [32]. 
Important  role in induction of those processes may
play also IGF-I receptor.  The cells treated for 24 h
with disintegrin and then for 24 h with melphalan
showed decreased expression of IGF receptor in com-
parison to the cells treated with both compounds sep-
arately. IGF-R is involved in regulation of cellular
growth and transformation [33]. Therefore inhibition
of the receptor expression may represent approach to
the inhibition of tumor growth. Blockade of the recep-
tor (34) or down regulation of its expression [35]
reduces cancer proliferation and induces apoptosis.
Decreased expression of the receptor by echistatin and
melphalan could explain decreased biosynthesis of
collagen in the cells, since IGF-I is a most potent
inducer of collagen biosynthesis [36]. 
Finally, echistatin (that by itself is only slightly
cytotoxic for Ishikawa cells) strongly potentiate cyto-
toxic effect of melphalan on this cells. 
The data presented suggest that combined therapy
with disintegrin – echistatin and alkyalting drug –
mephalan may represent a new approach to more
effective and safe endometrial cancer therapy.
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